Literature DB >> 33499248

Interaction between ERAP Alleles and HLA Class I Types Support a Role of Antigen Presentation in Hodgkin Lymphoma Development.

Peijia Jiang1,2, Rianne N Veenstra1, Annika Seitz1, Ilja M Nolte3, Bouke G Hepkema4, Lydia Visser1, Anke van den Berg1, Arjan Diepstra1.   

Abstract

Genetic variants in the HLA region are the strongest risk factors for developing Hodgkin lymphoma (HL), suggesting an important role for antigen presentation. This is supported by another HL-associated genomic region which contains the loci of two enzymes that process endogenous proteins to peptides to be presented by HLA class I, i.e., endoplasmic reticulum aminopeptidase 1 (ERAP1) and ERAP2. We hypothesized that ERAP and HLA class I type interact in HL susceptibility, as shown previously for several autoimmune diseases. We detected ERAP1 and ERAP2 expression in tumor cells and cells in the microenvironment in primary HL tissue samples. Seven ERAP SNPs and ERAP1 haplotypes showed strong associations with RNA and protein levels of ERAP1 and ERAP2 in LCLs and HL cell lines. Analysis of HLA class I types, ERAP SNPs and ERAP haplotypes by direct genotyping or imputation from genome-wide association data in 390 HL patients revealed significant interactions between HLA-A11, rs27038 and the rs27038 associated ERAP haplotype, as well as between HLA-Cw2 and rs26618. In conclusion, our results show that ERAP and HLA class I interact in genetic susceptibility to HL, providing further evidence that antigen presentation is an important process in HL susceptibility and pathogenesis.

Entities:  

Keywords:  ERAP1; ERAP2; HLA class I; Hodgkin lymphoma; SNP; susceptibility

Year:  2021        PMID: 33499248      PMCID: PMC7865538          DOI: 10.3390/cancers13030414

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  66 in total

1.  Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation.

Authors:  Matthew Stephens; Paul Scheet
Journal:  Am J Hum Genet       Date:  2005-01-31       Impact factor: 11.025

2.  Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4.

Authors:  R Gavioli; M G Kurilla; P O de Campos-Lima; L E Wallace; R Dolcetti; R J Murray; A B Rickinson; M G Masucci
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

3.  An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides.

Authors:  Tomo Saric; Shih-Chung Chang; Akira Hattori; Ian A York; Shirley Markant; Kenneth L Rock; Masafumi Tsujimoto; Alfred L Goldberg
Journal:  Nat Immunol       Date:  2002-11-18       Impact factor: 25.606

Review 4.  Regulation of ERAP1 and ERAP2 genes and their disfunction in human cancer.

Authors:  Mirco Compagnone; Loredana Cifaldi; Doriana Fruci
Journal:  Hum Immunol       Date:  2019-02-27       Impact factor: 2.850

5.  Prevalence and prognostic significance of Epstein-Barr virus infection in classical Hodgkin's lymphoma: a meta-analysis.

Authors:  Ju-Han Lee; Younghye Kim; Jung-Woo Choi; Young-Sik Kim
Journal:  Arch Med Res       Date:  2014-06-14       Impact factor: 2.235

6.  Genetic Variants in ERAP1 and ERAP2 Associated With Immune-Mediated Diseases Influence Protein Expression and the Isoform Profile.

Authors:  Aimee L Hanson; Thomas Cuddihy; Katelin Haynes; Dorothy Loo; Craig J Morton; Udo Oppermann; Paul Leo; Gethin P Thomas; Kim-Anh Lê Cao; Tony J Kenna; Matthew A Brown
Journal:  Arthritis Rheumatol       Date:  2017-12-29       Impact factor: 10.995

7.  Morphologic, immunologic, enzymehistochemical and chromosomal analysis of a cell line derived from Hodgkin's disease. Evidence for a B-cell origin of Sternberg-Reed cells.

Authors:  S Poppema; B De Jong; J Atmosoerodjo; V Idenburg; L Visser; L De Ley
Journal:  Cancer       Date:  1985-02-15       Impact factor: 6.860

8.  Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1.

Authors:  Yohei Kirino; George Bertsias; Yoshiaki Ishigatsubo; Nobuhisa Mizuki; Ilknur Tugal-Tutkun; Emire Seyahi; Yilmaz Ozyazgan; F Sevgi Sacli; Burak Erer; Hidetoshi Inoko; Zeliha Emrence; Atilla Cakar; Neslihan Abaci; Duran Ustek; Colleen Satorius; Atsuhisa Ueda; Mitsuhiro Takeno; Yoonhee Kim; Geryl M Wood; Michael J Ombrello; Akira Meguro; Ahmet Gül; Elaine F Remmers; Daniel L Kastner
Journal:  Nat Genet       Date:  2013-01-06       Impact factor: 38.330

9.  Functionally distinct ERAP1 and ERAP2 are a hallmark of HLA-A29-(Birdshot) Uveitis.

Authors:  Jonas J W Kuiper; Jessica van Setten; Matthew Devall; Mircea Cretu-Stancu; Sanne Hiddingh; Roel A Ophoff; Tom O A R Missotten; Mirjam van Velthoven; Anneke I Den Hollander; Carel B Hoyng; Edward James; Emma Reeves; Miguel Cordero-Coma; Alejandro Fonollosa; Alfredo Adán; Javier Martín; Bobby P C Koeleman; Joke H de Boer; Sara L Pulit; Ana Márquez; Timothy R D J Radstake
Journal:  Hum Mol Genet       Date:  2018-12-15       Impact factor: 6.150

10.  Variation at 3p24.1 and 6q23.3 influences the risk of Hodgkin's lymphoma.

Authors:  Matthew Frampton; Miguel Inacio da Silva Filho; Peter Broderick; Hauke Thomsen; Asta Försti; Jayaram Vijayakrishnan; Rosie Cooke; Victor Enciso-Mora; Per Hoffmann; Markus M Nöthen; Amy Lloyd; Amy Holroyd; Lewin Eisele; Karl-Heinz Jöckel; Sabine Ponader; Elke Pogge von Strandmann; Tracy Lightfoot; Eve Roman; Annette Lake; Dorothy Montgomery; Ruth F Jarrett; Anthony J Swerdlow; Andreas Engert; Kari Hemminki; Richard S Houlston
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more
  2 in total

1.  HLA Expression in Relation to HLA Type in Classic Hodgkin Lymphoma Patients.

Authors:  Geok Wee Tan; Peijia Jiang; Ilja M Nolte; Kushi Kushekhar; Rianne N Veenstra; Bouke G Hepkema; Ruth F Jarrett; Anke van den Berg; Arjan Diepstra
Journal:  Cancers (Basel)       Date:  2021-11-20       Impact factor: 6.639

2.  Killer Cell Immunoglobulin-Like Receptor Haplotype B Modulates Susceptibility to EBV-Associated Classic Hodgkin Lymphoma.

Authors:  Peijia Jiang; Ilja M Nolte; Bouke G Hepkema; Marijke Stulp; Anke van den Berg; Arjan Diepstra
Journal:  Front Immunol       Date:  2022-01-27       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.